News

18^thFebruary 2010 - Isogenica announces new partnership with UK MoD agency.

18^thJanuary 2010 - Phylogica and Isogenica target peptide drugs for inflammatory disease.

18^thFebruary 2009 - Isogenica relocates its research facility to Chesterford Research Park.

10^thFebruary 2009 - Isogenica nominated in the Rising Star of the Year category of the Cambridge Evening News Business Excellence Awards 2009.

16^thSeptember 2008 - Isogenica enters into an evaluation agreement with Pfizer.

12^thSeptember 2008 - Isogenica enters into a license agreement with Centocor Research & Development, Inc.

6^thMay 2008 - Isogenica completes acquisition of the principal assets of Karyon CTT.

6^th June 2007 - Isogenica Enters Into Research and License Agreement With Wyeth.

6^thNovember 2006 - Isogenica enters into a research and licence option agreement with UCB.

13^thJuly 2006 - Isogenica Renews Research Collaboration with AstraZeneca.

15^thJune 2006 - Isogenica announces the appointment of two non-executive directors.

8^thMay 2006 - Isogenica Enters into Research Collaboration with GE Healthcare.

1^stMarch 2006 - Isogenica closes new round of funding.

7^thNovember 2005 - Isogenica enters into research collaboration with Amgen.

17^thJanuary 2005 - Isogenica enters into research collaboration with NeuroTargets Ltd.

19^thMay 2004 - Isogenica enters into a research collaboration with AstraZeneca.

19^thMarch 2004 - Isogenica publishes key paper describing its proprietary CIS display in PNAS.

13^thMarch 2004 - Isogenica enters into a license and option agreement with Sangamo Biosciences.

10^thDecember 2003 - Isogenica signs an evaluation agreement with Johnson & Johnson Pharmaceuticals.

7^thMay 2003 - Isogenica signs an exclusive enabling agreement with Smiths Detection.

8^thJuly 2002 - Isogenica enters research collaboration with Graseby Dynamics.

20^thMay 2002 - Invitrogen signs option agreement to license Isogenica’s covalent display technology. (For information on Covalent Display Technology please click)

1^stOct 2001 - Affitech and Isogenica agree exclusive license to novel discovery technology for human antibodies.

1^stApril 2001 - Isogenica announces launch of company.